The 24/7 Global Portal

World News, Markets & Google Trends

Aggregated real-time headlines, trending Google search queries, and verified dispatches in one single page.

Google Trends:montez sweat1000+rob lowe1000+tanner hudson500+frozen frenzy200+payton pritchard1000+huevo500+winter weather advisory2000+joão cancelo1000+

Category:All Headlines World & Geopolitics Markets & Economy Tech & AI PoliticsSearch results for: "FDA Approves Nipocalimab-" (30 stories)

FDA approves IMAAVY® (nipocalimab-aahu) as first-ever treatment for warm autoimmune hemolytic anemia (wAIHA), representing a landmark advancement for patients

Lead StoryPR Newswiretech

Aug 24

FDA approves IMAAVY® (nipocalimab-aahu) as first-ever treatment for warm autoimmune hemolytic anemia (wAIHA), representing a landmark advancement for patients

<a href="https://news.google.com/rss/articles/CBMisgJBVV95cUxOWWhuSXBROXpxLVhpZlFzWDh2VDhURjNRc1BuQXV6V3g4MUJXQUljRjlTTGxyXy00OE9oemhkY2dPa29HT0hDUDlSeDVFVVhvblRzVWFUNFlmY2ZEeWdFbEMtYXV5QW1Fb2ZfZ2tIZ1V1QjhzWUJlX2NTc2RLc2RjLWhrY01PZzJzSldwbHgzS2ZLS2NOMTg4bVd3YWFRVnc3OGVqTDNHUk41cVZKZWk4RndaN2JNUXFCY3RfU050MlRuWVl3Rkl4OG1kenlBTk1jOFpDN3NIZmdBSmNPWlJGVGlSSU0tUS15YlpyODNrcExieHdBTVk4VDhPRU9TYlUtbEhHekhzdGxqczA0S0R5eHdHWS1WYmh5SXplSUFRREk5WURNdGJUODk2LU5wZDczVnc?oc=5" target="_blank">FDA approves IMAAVY® (nipocalimab-aahu) as first-ever treatment for warm autoimmune hemolytic anemia (wAIHA), representing a landmark advancement for patients</a>&nbsp;&nbsp;PR Newswire

Read Full Story Related Trends

Google Trends & Trending Search Intelligence

Real-time search volume

1000+21m ago

montez sweat

Bears DE Montez Sweat suspended 2 days for drug violation

Filter stories

1000+31m ago

rob lowe

Daily Wire's 'Confession': Details Revealed For James Franco, Rob Lowe Film

Filter stories

500+31m ago

tanner hudson

Bengals tight end Tanner Hudson out for season with torn pec

Filter stories

200+31m ago

frozen frenzy

The top reason to watch every NHL team in the Frozen Frenzy

Filter stories

Search Results for "FDA Approves Nipocalimab-"

Updated every 3 minutes via FreeNewsApi, GNews, Currents API & Google News

29 stories displayed

FDA Approves Nipocalimab-aahu as First Treatment for wAIHA

The American Journal of Managed Caretech

Aug 25

FDA Approves Nipocalimab-aahu as First Treatment for wAIHA

<a href="https://news.google.com/rss/articles/CBMijAFBVV95cUxQOE94TE4wZmxRTzI5d1J4aUMtLUlLNjlrVTJldjl3YzZIWlVaMzJBY3gxaEpBUzV0SVV1SlFBRUJqVGIxMGNmTnAxUWhLNno0MTFVVFo1cHJpbi1VY05JNVFmenRITDFTbFZYWWFWUjVPV0NzbGlJd3RVa1BqemJRQ1JhQW9XRU95ZzM1dw?oc=5" target="_blank">FDA Approves Nipocalimab-aahu as First Treatment for wAIHA</a>&nbsp;&nbsp;The American Journal of Managed Care

World News, Markets & Google Trends

Top Headline Story

FDA approves IMAAVY® (nipocalimab-aahu) as first-ever treatment for warm autoimmune hemolytic anemia (wAIHA), representing a landmark advancement for patients

Google Trends & Trending Search Intelligence

montez sweat

rob lowe

tanner hudson

frozen frenzy

Search Results for "FDA Approves Nipocalimab-"

FDA Approves Nipocalimab-aahu as First Treatment for wAIHA

FDA Approves IMAAVY (Nipocalimab) for Warm Autoimmune Hemolytic Anemia

FDA Approves Nipocalimab for Warm Autoimmune Hemolytic Anemia

FDA Approves First Treatment for Warm Autoimmune Hemolytic Anemia

FDA Approves Imaavy for Warm Autoimmune Hemolytic Anemia in Patients Aged 12 and Older

FDA Approves J&amp;J's IMAAVY as First Treatment for Warm Autoimmune Hemolytic Anemia

FDA Approves First Treatment for Warm Autoimmune Hemolytic Anemia

FDA approves J&amp;J's Imaavy (nipocalimab) as first-ever treatment for warm autoimmune haemolytic anaemia

FDA Approves IMAAVY as First-Ever Treatment for Warm Autoimmune Hemolytic Anemia

Warm autoimmune hemolytic anemia: first FDA-approved therapy arrives with nipocalimab

FDA Approves Imaavy for wAIHA | PharmExec

Johnson &amp; Johnson seeks FDA approval of IMAAVY® as the first-ever FDA-approved treatment for warm autoimmune hemolytic anemia

Durable Benefit for Nipocalimab in gMG Across Age Groups

FDA Priority Review Advances Nipocalimab for Adults With Warm Autoimmune Hemolytic Anemia

Nipocalimab Improves gMG Outcomes Across East Asian Subgroup

FDA Approves Nipocalimab for Adult and Pediatric Myasthenia Gravis

FDA Approves Nipocalimab for Generalized Myasthenia Gravis

Top 5 Myasthenia Gravis Content of 2025

FDA Approves Nipocalimab for the Treatment of Generalized Myasthenia Gravis

FDA Approves FcRn Blocker Nipocalimab for Broad Forms of Generalized Myasthenia Gravis

FDA approves nipocalimab-aahu to treat generalized myasthenia gravis

FDA Approves Nipocalimab-Aahu to Treat Patients With Generalized Myasthenia Gravis

FDA Approves Johnson &amp; Johnson’s IMAAVY™ (nipocalimab-aahu) a New Treatment for Myasthenia Gravis (MG), Offering Hope for Families

FDA approves J&amp;J’s nipocalimab, now Imaavy, to treat gMG

FDA Approves Nipocalimab Generalized Myasthenia Gravis for Adults, Children

FDA approves J&amp;J’s FcRn blocker for generalized myasthenia gravis

Johnson &amp; Johnson receives FDA approval for IMAAVY™ (nipocalimab-aahu), a new FcRn blocker offering long-lasting disease control in the broadest population of people living with generalized myasthenia gravis (gMG)

FDA Approves New Monoclonal Antibody for Myasthenia Gravis

A Closer Look at Nipocalimab’s Impact on Myasthenia Gravis Care: Constantine Farmakidis, MD

FDA Approves J&J's IMAAVY as First Treatment for Warm Autoimmune Hemolytic Anemia

FDA approves J&J's Imaavy (nipocalimab) as first-ever treatment for warm autoimmune haemolytic anaemia

Johnson & Johnson seeks FDA approval of IMAAVY® as the first-ever FDA-approved treatment for warm autoimmune hemolytic anemia

FDA Approves Johnson & Johnson’s IMAAVY™ (nipocalimab-aahu) a New Treatment for Myasthenia Gravis (MG), Offering Hope for Families

FDA approves J&J’s nipocalimab, now Imaavy, to treat gMG

FDA approves J&J’s FcRn blocker for generalized myasthenia gravis

Johnson & Johnson receives FDA approval for IMAAVY™ (nipocalimab-aahu), a new FcRn blocker offering long-lasting disease control in the broadest population of people living with generalized myasthenia gravis (gMG)